EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL‐C Levels

Eléonore Maury, Samuel Brouyère, Mieke Jansen

Clinical Cardiology · 2024

DOI: 10.1002/clc.24330 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Eléonore Maury und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department, Novartis Pharma, Vilvoorde, Belgium. Hauptthemen laut MEDLINE: Cholesterol, LDL, Atherosclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was funded by Novartis Pharma Belgium..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dyslipidemia remains the major cause of atherosclerotic cardiovascular disease (ASCVD). Lipid management in patients with increased cardiovascular (CV) risk needs improvement across Europe, and data gaps are noticeable at the country level. Hypothesis We described the current treatment landscape in Belgium, hypothesizing that lipid management in patients with ASCVD remains inadequate and aiming to understand the reasons.

Methods

Using data from an anonymized primary care database in Belgium derived from 494 750 individuals, we identified those with any CV risk factor between November 2019 and October 2022 and described the clinical features of patients with ASCVD. The main outcomes were the proportion of patients (i) receiving lipid‐lowering therapies (LLTs), (ii) per low‐density lipoprotein cholesterol (LDL‐C) threshold, stratified per LLT, (iii) reaching the 2021 ESC recommended LDL‐C goals, and (iv) LDL‐C reduction per type of LLT was also determined.

Results

Among 40 888 patients with very high CV risk, 24 859 had established ASCVD. Most patients with ASCVD were either receiving monotherapy (59.6%) or had no documented LLT (25.1%). Further, 64.2% of those with no documented LLT exhibited LDL‐C levels ≥ 100 mg/dL. Among common treatment options, one of the greatest improvements in LDL‐C levels was achieved with combination therapy of statin and ezetimibe, reducing LDL‐C levels by 41.5% ( p < 0.0001). Yet, in this group, 24.8% of patients had still LDL‐C levels ≥ 100 mg/dL and only 20.7% were at goal.

Conclusion

Our study emphasizes the importance of developing strategies to help patients achieve their LDL‐C goals, with a focus on supporting the implementation of combination LLT in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLAtherosclerosisHumansBelgiumMaleFemaleMiddle AgedAgedHydroxymethylglutaryl-CoA Reductase InhibitorsBiomarkersRetrospective StudiesDyslipidemiasRisk FactorsHypolipidemic AgentsPractice Patterns, Physicians'Treatment Outcome

Stichwörter der Autor:innen

atherosclerotic cardiovascular diseasegeneral practitionershigh cardiovascular risklipid‐lowering therapyreal‐world evidence

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsBiomarkersHypolipidemic Agents

Autor:innen und Institutionen

  • Medical Department, Novartis Pharma, Vilvoorde, Belgium.
  • Cegedim Health Data Belgium, Brussels, Belgium.

Förderung

  • This work was funded by Novartis Pharma Belgium.

Zitieren

APA

Maury, E., Brouyère, S., & Jansen, M. (2024). Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL‐C Levels. Clinical Cardiology. https://doi.org/10.1002/clc.24330

Vancouver

Maury E, Brouyère S, Jansen M. Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL‐C Levels. Clinical Cardiology. 2024. doi:10.1002/clc.24330

BibTeX
@article{Maury2024,
  author = {Maury, Eléonore and Brouyère, Samuel and Jansen, Mieke},
  title = {Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL‐C Levels},
  journal = {Clinical Cardiology},
  year = {2024},
  doi = {10.1002/clc.24330}
}
Kostenlos starten →